By Frank Prenesti
Date: Monday 22 Sep 2025
(Sharecast News) - AstraZeneca and Amgen on Monday said their Tezspire drug has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.
| SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
| Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
| Tech Ticker | 16-Dec-2010 | BayArea.com |
| Amgen drug delayed spread of prostate cancer to ... | 15-Dec-2010 | LA Times |
| Business Briefing | 24-Dec-2009 | LA Times |
| Currency | US Dollars |
| Share Price | $ 319.86 |
| Closing Price Change | $ 23.16 |
| % Change | 0.00 % |
| 52 Week High | $327.36 |
| 52 Week Low | $258.59 |
| Volume | 0 |
| Shares Issued | 536.90m |
| RiskGrade | 100 |
| Strong Buy | 6 |
| Buy | 7 |
| Neutral | 15 |
| Sell | 2 |
| Strong Sell | 1 |
| Total | 31 |

| Time | Volume / Share Price |
| 13:09 | 40 @ $317.02 |
| 13:09 | 120 @ $317.08 |
| 13:09 | 40 @ $317.02 |
| 13:09 | 57 @ $317.02 |
| 13:09 | 50 @ $317.02 |
You are here: research